Veracyte Q3 revenue $115.9M (+29% YoY), net income $15.2M

VERACYTE, INC.

2024-Q3 EPS reported $0.25 revenue$327,132,000

Testing revenue $109.5M (+34%); total testing volume 36,792 (+24%); total tests 39,032 (+20%).
Decipher revenue +48%, volume +36% (21,250 tests); Afirma revenue +19%, volume +12% (15,100 tests).
GAAP net income $15.2M; adjusted EBITDA $27.3M (24% margin); operating cash flow $30.0M.
Presented Decipher Prostate clinical data from STAMPEDE (ESMO) and VANDAAM (ASTRO); added two directors and SVP of Operations.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.